Search

Your search keyword '"Lee, Byung Ha"' showing total 333 results

Search Constraints

Start Over You searched for: Author "Lee, Byung Ha" Remove constraint Author: "Lee, Byung Ha" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
333 results on '"Lee, Byung Ha"'

Search Results

7. Investigation of a potential protein biomarker signature that may predict clinical benefit of NT-I7 and pembrolizumab in patients with cold gastrointestinal tumors.

8. Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer

10. Targeting ROS-sensing Nrf2 potentiates anti-tumor immunity of intratumoral CD8+T and CAR-T cells

14. CTIM-33. EFFICACY AND SAFETY STUDY OF NEOADJUVANT EFINEPTAKIN ALFA (NT-I7) AND PEMBROLIZUMAB IN RECURRENT GLIOBLASTOMA

15. EXTH-52. LONG-ACTING RECOMBINANT INTERLEUKIN-7, NT-I7, IMPROVES SURVIVAL FOLLOWING ONCOLYTIC ZIKA VIRUS TREATMENT IN THE SB28 IMMUNOSUPPRESSIVE AND TREATMENT-RESISTANT MURINE GLIOMA MODEL

16. 652 NT-I7 (efineptakin alfa), a long-acting IL-7, in combination with pembrolizumab improves T cell fitness in heavily pretreated subjects with gastrointestinal tumors

20. Supplementary Figure from Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models

21. Supplementary Data from Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models

24. Aquaculture Farm Facility Loss Management System

25. Improvement of u-Multiplex Services

27. A Phase 1b Dose Expansion Study Evaluating Safety, Preliminary Anti-Tumor Activity, and Accelerated T Cell Reconstitution with NT-I7 (Efineptakin Alfa), a Long-Acting Human IL-7, Administered Following Tisagenlecleucel in Subjects with Relapsed/Refractory Large B-Cell Lymphoma

28. 657 NT-I7, a long-acting IL-7, plus pembrolizumab favors CD8 T-cell infiltration in liver metastases of heavily pre-treated, immunologically cold, MSS-colorectal and pancreatic cancer

33. A phase 1b/2a study of safety and efficacy of NT-I7 in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 naïve or relapsed/refractory (R/R) high-risk skin cancers: The phase 1b report.

36. Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models

39. CTIM-07. A PHASE I/II STUDY EVALUATING THE SAFETY AND EFFICACY OF A NOVEL LONG-ACTING INTERLEUKIN-7, NT-I7, FOR PATIENTS WITH NEWLY DIAGNOSED HIGH-GRADE GLIOMAS AFTER CHEMORADIOTHERAPY

40. 396 NT-I7, a long-acting interleukin-7, promotes expansion of CD8 T cells and NK cells and immune activation in patients with newly diagnosed high-grade gliomas after chemoradiation

41. 404 Initial biomarker and clinical data of a phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: cohort of subjects with checkpoint inhibitor-naïve advanced MSS-colorectal cancer

42. 408 Preliminary biomarker and clinical ata of a phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: cohort of subjects with checkpoint inhibitor-naïve advanced pancreatic cancer

48. Electrothermal-chemical ignition research on 120-mm gun in Korea

Catalog

Books, media, physical & digital resources